Belite Bio Common Stock

The latest common stock for BLTE is $800M as of March 2026. That compares with $160M in the prior-year period — up 403.4% year over year. Investors often review this figure alongside Belite Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, BLTE's common stock moved from $160M to $800M — a 403.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Belite Bio's operating scale or balance-sheet position.

A common stock figure of $800M for BLTE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BLTE's common stock ($800M), review year-over-year change from $160M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.